Cargando…
Inhaled corticosteroid dose is associated with Pseudomonas aeruginosa infection in severe COPD
INTRODUCTION: Patients with chronic obstructive pulmonary disease (COPD) with frequent exacerbations (ExCOPD) are commonly treated with inhaled corticosteroids (ICS) and are at risk of infections caused by potential pathogenic bacteria (PPB) including Pseudomonas aeruginosa (PsA). OBJECTIVES: To inv...
Autores principales: | Shafiek, Hanaa, Verdú, Javier, Iglesias, Amanda, Ramon-Clar, Lluisa, Toledo-Pons, Nuria, Lopez-Causape, Carla, Juan, Carlos, Fraile-Ribot, Pablo, Oliver, Antonio, Cosio, Borja G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496398/ https://www.ncbi.nlm.nih.gov/pubmed/34615691 http://dx.doi.org/10.1136/bmjresp-2021-001067 |
Ejemplares similares
-
Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD
por: Kreindler, James L, et al.
Publicado: (2016) -
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016) -
Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease
por: Eklöf, Josefin, et al.
Publicado: (2022) -
Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity
por: van den Berge, Maarten, et al.
Publicado: (2014) -
Withdrawal of inhaled corticosteroids from patients with COPD with mild or moderate airflow limitation in primary care: a feasibility randomised trial
por: Harries, Timothy H, et al.
Publicado: (2022)